RE: Exit price9 Apr 2021 12:05
Hi Ferraro,
I respect your point of view but beg to differ. The lack of communication is a tad frustrating, though FDA is outside of DB or anyone else's control.
For all we know sales could be progressing well. It would be prudent for labs to use up any supplies from other companies before buying new stock from GDR. This is all part of the sales cycle and is perfectly normal in all business settings.
GLA.